Skip to content
Search

Latest Stories

RPS publishes roadshow report, membership vote on Royal College status set for Q1 2025

RPS gathers feedback on its proposals for change and its ambition to transition into the Royal College of Pharmacy.

Pharmacists and pharmaceutical scientists provide feedback on proposed changes to the RPS constitution and governance (C&G)  

The Royal Pharmaceutical Society (RPS) has released a comprehensive report summarizing the discussions and feedback gathered during a series of engagement events held across Great Britain in October and November, focused on its proposals for change and its ambition to transition into the Royal College of Pharmacy.


The engagement initiative included 15 roadshow events in various cities across England, Wales, and Scotland, as well as online events and meeting presentations.

According to the report, the roadshows attracted over 1,000 registrations, with more than 540 attendees.

Hosted by the RPS leadership team and elected officials, these events brought together a diverse group of pharmacists, foundation trainees, pharmaceutical scientists, and other stakeholders from different settings and sectors.

Participants shared their thoughts on the RPS’s proposals to reform its constitution and governance, raised critical questions, and explored the implications of the proposed changes.

RPS president Professor Claire Anderson highlighted the significance of these roadshows, stating that they have provided “an invaluable opportunity to connect with members and non-members and hear their thoughts about the proposed changes, and what becoming a Royal College would mean to them and for pharmacy.”

“We are grateful for the enthusiasm, insights, and constructive feedback shared by everyone who came to one of the events. This dialogue is vital as we move forward with our proposals for change and seek to elevate pharmacy and champion our collective impact on patient care.”

The RPS said that it has taken into account the questions and feedback from members and stakeholders in the final drafting of their proposals for change, which will be published this month.

As part of the next steps in the constitution and governance (C&G) process, RPS plans to launch a campaign to inform and engage its members, leading up to a membership vote on the Royal College status in Q1 2025.

  • The current proposals include making these key changes:
  • Transforming RPS into a registered charity, overseen by a Board of Trustees.
  • Seeking to become the Royal College of Pharmacy.
  • Retaining an elected body for professional leadership, transitioning from the current Assembly to a Senate with clearly defined roles.
  • Maintaining National Boards, to be renamed National Councils, focusing on devolved national health policy.
  • Establishing Pharmaceutical Press as a wholly owned subsidiary.

For the changes to be enacted, a two-thirds majority of members’ votes in favour is required, along with approval from the Privy Council.

Additionally, obtaining charitable status necessitates agreement from charity regulators in England, Wales, and Scotland.

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less